Effectiveness of olanzapine in patients who fail therapy with aprepitant while receiving highly emetogenic chemotherapy.

about

Effectiveness of olanzapine in patients who fail therapy with aprepitant while receiving highly emetogenic chemotherapy.

Item

http://www.wikidata.org/entity/Q47296270

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Effectiveness of olanzapine in ...... ighly emetogenic chemotherapy.

@en

Effectiveness of olanzapine in ...... ighly emetogenic chemotherapy.

@nl

type

Item

label

Effectiveness of olanzapine in ...... ighly emetogenic chemotherapy.

@en

Effectiveness of olanzapine in ...... ighly emetogenic chemotherapy.

@nl

prefLabel

Effectiveness of olanzapine in ...... ighly emetogenic chemotherapy.

@en

Effectiveness of olanzapine in ...... ighly emetogenic chemotherapy.

@nl

P1476

Effectiveness of olanzapine in ...... highly emetogenic chemotherapy

@en

P2093

Abirami Boopathy

http://www.w3.org/2001/XMLSchema#string

Manikandan Dhanushkodi

http://www.w3.org/2001/XMLSchema#string

Sevaluxmy Ganesharajah

http://www.w3.org/2001/XMLSchema#string

Surendran Veeriah

http://www.w3.org/2001/XMLSchema#string

Swaminathan Rajaraman

http://www.w3.org/2001/XMLSchema#string

Tenali Gnana Sagar

http://www.w3.org/2001/XMLSchema#string

Trivadi S Ganesan

http://www.w3.org/2001/XMLSchema#string

P2860

Olanzapine for the prevention and treatment of chronic nausea and chemotherapy-induced nausea and vomiting.

Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment.

A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.

Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.

The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy.

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.

Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.

Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study.

P2888

s12032-017-1074-3

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12032-017-1074-3

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Venkatraman Radhakrishnan

Nikita Mehra

Prasanth Ganesan

P577

2017-12-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29248965

http://www.w3.org/2001/XMLSchema#string